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ABSTRACT
The clinical application of central nervous system (CNS) drugs is limited by their poor bioavailability
due to the blood–brain barrier (BBB). Borneol is a naturally occurring compound in a class of ‘orifice-
opening’ agents often used for resuscitative purposes in traditional Chinese medicine. A growing body
of evidence confirms that the ‘orifice-opening’ effect of borneol is principally derived from opening the
BBB. Borneol is therefore believed to be an effective adjuvant that can improve drug delivery to the
brain. The purpose of this paper is to provide a comprehensive review of information accumulated
over the past two decades on borneol’s chemical features, sources, toxic and kinetic profiles, enhanc-
ing effects on BBB permeability and their putative mechanisms, improvements in CNS drug delivery,
and pharmaceutical forms. The BBB-opening effect of borneol is a reversible physiological process char-
acterized by rapid and transient penetration of the BBB and highly specific brain regional distribution.
Borneol also protects the structural integrity of the BBB against pathological damage. The enhance-
ment of the BBB permeability is associated with the modulation of multiple ATP-binding cassette trans-
porters, including P-glycoprotein; tight junction proteins; and predominant enhancement of
vasodilatory neurotransmitters. Systemic co-administration with borneol improves drug delivery to the
brain in a region-, dose- and time-dependent manner. Several pharmaceutical forms of borneol have
been developed to improve the kinetic and toxic profiles of co-administered drugs and enhance their
delivery to the brain. Borneol is a promising novel agent that deserves further development as a BBB
permeation enhancer for CNS drug delivery.
ARTICLE HISTORY
Received 23 May 2017
Revised 19 June 2017






Although considerable advancements have been made in
drug delivery to the central nervous system (CNS), the clinical
application of CNS drugs is still limited by their poor bioavail-
ability due to the blood–brain barrier (BBB) (Pardridge, 2005;
Denora et al., 2009). The special anatomic features of the BBB
protect the CNS from toxins and variations in blood compos-
ition, and maintain the constancy of the brain’s micro-envir-
onment (Abbott & Friedman, 2012). The BBB is a physical
and metabolic barrier that restricts the penetration of mole-
cules (Pardridge, 2005). A key determinant of the kinetic and
therapeutic properties of CNS drugs is their ability to cross
the BBB (Fu, 2012). The temporary opening of the paracellu-
lar pathway of the BBB is believed to be an effective strategy
to enhance drug delivery to the brain (Pardridge, 2005;
Shi et al., 2014a,b).
In traditional Chinese medicine (TCM), a group of drugs is
specifically used for resuscitative purposes to restore con-
sciousness in cases of coma, heart attack, stroke, traumatic
brain injury and other brain-related emergency conditions.
Most TCM resuscitation agents are derived from aromatic
mineral and animal materials and are referred to as aromatic
‘orifice-opening’ agents (Wang et al., 2014). Borneol
(Bing-Pian or Long-Nao) is a representative TCM resuscitation
drug that has been used in clinical practice more than
1500 years. Borneol (C10H18O, molecular weight 154.25) is a
highly lipid-soluble bicyclic monoterpene with fragrant odor
and pungent and bitter tastes (Figure 1). Over the past two
decades, this traditional agent has attracted increasing atten-
tion as a novel agent that can easily and rapidly cross the
BBB due to its low molecular mass and high lipid solubility
(Xiong et al., 2013; Wang et al., 2014). Several studies have
been done to explore the ‘orifice-opening’ effects of borneol
and their underlying mechanisms (Xiong et al., 2013; Wang
et al., 2014). The objective of this paper is to provide a com-
prehensive review of borneol, including its chemical features,
sources, toxic and kinetic profiles, enhancing effects on the
BBB permeability and their putative mechanisms, improve-
ment in CNS drug delivery and pharmaceutical forms.
Sources
Borneol’s sources include natural extracts and artificial syn-
thesis. One natural form of borneol is dextrorotatory borneol
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(endo-(1 R)-1,7,7-trimethyl-bicyclo[2.2.1] heptan-2-ol, (þ)-bor-
neol), which traditionally originated from the resin of
Dipterocarpus aromatica Gaertn. f., a plant that grows in
Southeast Asia. Due to its rarity, the essential oil extracted
from the fresh branches and leaves of Cinnamomum
camphora (L.) Presl. has been widely used as a substitute.
Another natural form of borneol is levorotary borneol (endo-
(1 S)-1,7,7-trimethyl-bicyclo [2.2.1] heptan-2-ol, (–)-borneol),
which is extracted from fresh leaves of Blumea balsamifera
(L.) DC., a traditional medicinal plant commonly used by the
Miao minority in China (Wang et al., 2014). Synthetic borneol
is an optically inactive (±)-borneol that is a mixture of
(±)-borneol and isoborneol and is obtained via chemical
transformation of camphor and turpentine oil. Camphor is
the principal metabolite of borneol (Jiang et al., 2008).
Natural and synthetic borneol and their metabolite camphor
can be detected with gas chromatography and mass spec-
trometry (Cheng et al., 2013). For clinical use, the purity of
(þ)- and (–)-borneol must be no less than 96.0 and 85.0%,
respectively, whereas the purity of (±)-borneol should be no
less than 55.0% (State Pharmacopoeia Committee, 2015).
Toxicological profile
An ideal enhancer of the BBB permeability should be stable,
nontoxic, nonirritant and compatible with other compounds
(Banks, 2009). Natural borneol has been extensively used in
aromatherapy and in natural and cosmetic products because
of its low toxicity compared to synthetic borneol, which tox-
icity is relatively high as it degrades slowly during storage,
and noxious camphor levels may vary from 45% to as high
as 97% (Zeng & He, 2004; Xiong et al., 2013; Wang et al.,
2014). However, due to its price advantage, synthetic borneol
is often used to replace natural borneol.
Median lethal dose (LD50) is the dose of a toxic agent that
is sufficient to kill 50% of a population of animals. Oral LD50
of borneol are 300–5800mg/kg in rodents and 3200mg/kg in
rabbits (https://www.ncbi.nlm.nih.gov/pccompound). The IC50
values, defined as the median inhibitory concentration that
causes 50% cell death, are 2.5–3.0mM for rat hepatocytes,
2750lM for HepG2 cells, 2250 lM for Caco-2 cells and
1500lM for VH10 cells (Slamenova et al., 2009). Cytotoxicity
of borneol at concentrations above IC50 manifests as geno-
toxicity with DNA damage. However, repeated administration
of borneol at daily concentrations of 17.14mg/kg and 34.
28mg/kg for 7 days reduced H2O2-induced DNA damage in
hepatocytes and testicular cells, respectively (Horvathova
et al., 2009), suggesting a difference in toxic response
between acute and chronic borneol regimens. No significant
toxic effects of borneol were observed in mouse oral fibro-
blasts at concentrations of 18.75–150lg/mL (Dai et al., 2009),
corneal tissue at a concentration of 0.1% (Yang et al., 2009),
or in rat thymocytes at a concentration of 5 lg/mL (Cherneva
et al., 2012). The doses of natural and synthetic borneol rec-
ommended for clinical use are 0.3–0.9 g and 0.15–0.3 g,
respectively (State Pharmacopoeia Committee, 2015).
Kinetic characteristics of borneol in peripheral
organs and the brain
Oral administration is most common in the clinical use of
borneol. Borneol is absorbed rapidly into the brain and can
be determined in the brain at the same concentration as in
the blood within 5min of oral administration, which suggests
that it can rapidly cross the BBB and enter brain tissues
(Liang et al., 1993). The maximum concentration (Cmax) in the
brain is reached within 1 h after dosing (Liang et al., 1993;
Li et al., 2012). Borneol has a relatively lower blood albumin
binding constant [2.4 103 (mol/L)1] and rate (59.5%) than
most other orally administered CNS drugs, for which brain
bioavailability is generally low due to the hepatic first-pass
effect, high plasma protein binding and hindrance by the
BBB (Hu & Chen, 2009). In mice, a single oral dose of borneol
accumulates in organs in the order of liver>brain>
kidney>heart> spleen>muscle> lung, which confirms its
considerably higher bioavailability in the brain than in most
other organs examined (Huang et al., 2009). The distribution
of borneol in the brain shows regional specificity, with the
concentration highest in the cortex, moderate in the hippo-
campus and hypothalamus and lowest in the striatum (Yu
et al., 2013a).
Intranasal drug delivery can avoid gastrointestinal destruc-
tion and hepatic first-pass metabolism, resulting in rapid
onset of effect and high brain bioavailability. It is therefore
considered to be an effective approach for borneol adminis-
tration. One study has compared the kinetic profile of bor-
neol administered via oral, intranasal, and intravenous route
(Zhao et al., 2012); the results are summarized in Table 1.
The blood absolute bioavailability associated with the intra-
nasal route is approximately twice that of the oral route and
is comparable to that of the intravenous route in mice (Zhao
et al., 2012). Similar results were also obtained in rats (Song
et al., 2012). However, the brain Cmax and brain/blood drug
ratio were similar for the intranasal and oral routes (Zhao
et al., 2012), which suggests that the delivery rate of borneol
into the brain does not differ between the oral and intranasal
routes.
Improvement of drug delivery to the brain
Evidence for improved drug delivery to the brain
A large body of evidence has confirmed the effects of bor-
neol in improving drug delivery to the brain (Table 2).
Systemic co-administration with borneol produced a
Figure 1. Molecular structures of borneol.
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26–197% increase in brain Cmax and AUC values of the co-
administered agents tetramethylpyrazine (ligustrazine) (Liu
et al., 2008; Xiao et al., 2008), nimodipine (Wu et al., 2014),
gastrodin (Cai et al., 2008), rifampicin (Wu et al., 2004), geni-
poside (Dong et al., 2012) and hyperforin (Yu et al., 2011b)
compared to the agents alone, indicating that the addition
of borneol enhances the transportation and bioavailability of
drugs in the brain. Furthermore, the brain bioavailability of
geniposide was approximately five times greater when it was
given by intranasal co-administration with borneol than
when the drugs were given by intragastric co-administration
(Lu et al., 2012).
Borneol co-administered orally with levodopa, a metabolic
precursor that is converted to dopamine in the brain and
mainly used for the treatment of Parkinson’s disease,
increased its Cmax by 115% and AUC by 12% in rat cerebro-
spinal fluid (CSF) (Xian et al., 2013). This finding raises the
possibility that, like carbidopa, which is always given in com-
bination with levodopa to prevent the metabolism of levo-
dopa in the periphery, borneol could serve as an enhancer to
facilitate the brain distribution and bioavailability of
levodopa, thus reducing the required dosage and related
side effects.
Brain-regional specificity of the improvement in CNS
drug delivery
Microdialysis studies have revealed that when geniposide
was given in combination with borneol, the accumulation
and bioavailability of geniposide largely improved in the
hippocampus and the hypothalamus, but was suppressed in
the cortex and unaltered in the striatum compared to geni-
poside alone (Yu et al., 2013a). Similar region-specific
enhancement by borneol was also observed for puerarin and
edaravone in the cortex (Gao et al., 2010), kaempferol in the
hippocampus (Zhang et al., 2015), meropenem in the stri-
atum (Xin et al., 2014) and ligustrazine in the hypothalamus
and the striatum (Yu et al., 2016). This may be directly associ-
ated with the brain region-specific distribution of borneol,
suggesting that borneol’s enhancement of CNS drug delivery
varies in different brain regions. The brain region-targeted
effect of borneol could help co-administered agents to gain
greater access to specific brain regions.
Dose- and time-dependent improvement in CNS drug
delivery
Systemic co-administration with borneol in low doses rang-
ing from 0.05 to 2.0 g/kg facilitated the delivery of genipo-
side to the rat brain, but high doses of 2.0–4.0 g/kg
suppressed geniposide delivery compared to administration
without borneol (Dong et al., 2012). Borneol also increased
the quantity and velocity of geniposide permeating the brain
and the effect reached the most obvious at 15min after both
agents were given simultaneously via the intragastric route
in rats (Yu et al., 2012). Similar results were observed for bor-
neol co-treatment with gastrodin in mice (Cai et al., 2008).
The enhancing effects on the brain bioavailability of gastrodi-
genin, an active metabolite of gastrodin, reached a peak level
with borneol doses of 200–600mg/kg, but were attenuated
with doses above 600mg/kg (Cai et al., 2008). When borneol
was given at different intervals, a robust enhancing effect on
Table 2. Borneol improves kinetic profile of co-administered agents in the brain.
Cmax (lg/g) AUC (lg/mL/min)
Borneol (mg/kg) Co-administered agents (mg/kg) Sample alone combined alone combined Ref.
30, i.g. TMPP, 37.5, i.g. Mouse brain homogenate 2.83 4.38 103.54 168.15 Xiao et al., (2008)
0.9, i.n. TMPP, 5, i.n. Rat brain homogenate 10.92 14.16 1.95a 2.80a Liu et al., (2008)
250, i.g. Nimodipine, 2, i.v. Mouse brain homogenate 21.86 28.42 Wu et al., (2014)
400, i.g. Gastrodin, 200, i.g. Mouse brain homogenate 0.50 0.63 50.12 104.67 Cai et al., (2008)
200, i.g. Geniposide, 300, i.v. Rat brain homogenate 19 37 810 2410 Dong et al., (2012)
600, i.g. Rifampicin, 182, i.g. Mouse brain homogenate 2.0 5.1 285.1 569.5 Wu et al., (2004)
300/600, i.g. Hyperforin, 200, i.g. Rat brain homogenate 0.13b 0.23–0.24 13.8 19.5–19.7 Yu et al., (2011b)
300, i.g. Levodopa, 416, i.g. Rat CSF 4.29b 9.00b 2587.5 2890.4 Xian et al., (2013)
300, i.g. Puerarin, 62.5, i.v. Rat cortex 117.6 341.8 Gao et al., (2010)
300, i.g. Edaravone, 3.75, i.v. Rat cortex 50.83 70.29 Gao et al., (2010)
30, i.v. Kaempferol, 25, i.v. Rat hippocampus 0.11 0.35 13.06 28.57 Zhang et al., (2015)
186, i.g. Meropenem, 208, i.p. Rat striatum 1.20 2.25 122.56 233.25 Xin et al., (2014)




Table 1. Comparisons of kinetic profile of orally, intranasally and intravenously
administered borneol in mice using the noncompartmental model.
i.v. i.n. p.o.
Plasmaa
Cmax (lg/mL) 68.0 ± 8.4 25.9 ± 5.0 15.6 ± 2.3
Tmax (min) 1.0 3.0 10.0
AUC0–120min (lgmL1min) 632.3 ± 50.8 573.4 ± 77.7 271.8 ± 37.4
MRT0–120min (min) 12.2 ± 1.6 28.2 ± 1.4 17.9 ± 2.1
F (%) 100 90.7 43.0
Brain
Cmax (lg/g) 43.0 ± 5.1 9.0 ± 1.4 8.5 ± 2.0
Tmax (min) 1.0 3.4 10.0
AUC0–120min (lgg1min) 505.3 ± 82.9 345.5 ± 70.0 194.0 ± 23.5
MRT0–120min (min) 20.5 ± 8.8 49.0 ± 8.3 43.6 ± 17.1
Re (%) 100 68.4 38.4
Te (%) 79.9 60.3 71.4
DTI 1.0 0.8 0.9
This table is modified based on Zhao et al. (2012). Data are expressed as
mean ± SD (n¼ 5). p< 0.05, p< 0.01: versus intravenous group, using
one-way analysis of variance (ANOVA). i.v.: intravenous administration; i.n.:
intranasal administration; p.o.: oral administration; Cmax: calculated maximum
concentration; Tmax: time corresponding to Cmax; AUC0–120min: partial area
under the curve from 0 to 120min; MRT0–120min: mean residence time from 0
to 120min; F: absolute bioavailability; Re: relative brain targeted coefficient;
Te: brain/blood drug ratio; DTI: drug target index.
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brain gastrodigenin bioavailability was achieved within
40min (Cai et al., 2008). Likewise, oral co-treatment with bor-
neol at doses of 15–90mg/kg, but not higher doses, pro-
duced a proportionally greater increase in plasma and brain
concentration of tetramethylpyrazine phosphate (TMPP) in
mice compared to treatment without borneol, particularly in
the early period (Xiao et al., 2007).
These studies indicate that borneol enhances CNS drug
delivery in a dose- and time-dependent manner. The optimal
dosing regimen of borneol that rapidly produces the max-
imum enhancement of brain delivery without unfavorable
side effects varies from one co-administered drug to another
and should be determined individually.
Borneol’s regulation of BBB permeability and
putative mechanisms
In vivo and in vitro evidence
An early dynamic computed tomographic study found that
arterial injection of borneol significantly enhanced the trans-
port of diatrizoate, a water-soluble contrast agent used dur-
ing radiography, into the rabbit brain (Wang et al., 1992).
Since then, a growing body of evidence has confirmed the
enhancing effects of borneol on BBB permeability (Zhai &
Shen, 2010). Evans blue is the marker most commonly used
to investigate BBB integrity and permeability because it binds
to albumin, a high-molecular weight protein that cannot
cross the BBB if the barrier is structurally and functionally
intact (Saunders et al., 2015). Experimental animal studies
have clearly demonstrated that systemic borneol significantly
increased the amount of Evans blue entering the brain
(Yu et al., 2011a; Zhai & Shen, 2010). Furthermore, repeated
systemic borneol significantly widened tight junctions and
increased the number of void structures between the endo-
thelial cells of the BBB examined with transmission electron
microscopy in the rat brain (Yu et al., 2013b).
The permeability-enhancing effect of borneol has been
further confirmed in in vitro experiments. Madin–Darby
canine kidney epithelial (MDCK) cell culture is a commonly
used cell model of the BBB because it displays several struc-
tural similarities to the BBB, including intercellular tight junc-
tions and other related subcellular components (Rodriguez-
Boulan et al., 2005). Borneol-containing serum added to
MDCK cells resulted in the loosening of intercellular tight
junction and in an increase in number and enlargement of
pinocytosis vesicles (Chen & Wang, 2004). The loosening of
tight junctions and enhanced pinocytosis, respectively, was
observed at 4 and 24 h after treatment with borneol but dis-
appeared at 24 h after removal of the borneol-containing
serum (Chen & Wang, 2004), which indicates that borneol
enhancement of BBB permeability is reversible and transient.
Inducible nitric oxide synthase (iNOS) is expressed only
after cell activation in response to pathological insults and
often serves as a biomarker to differentiate between physio-
logical and pathophysiological actions of nitric oxide (NO)
(Kr€oncke et al., 1998). The level of iNOS expression in brain
microvascular endothelial cells was strikingly increased in rats
with brain traumatic injury but was unchanged in intact rats
(Zhao et al., 2002). Oral borneol given 6 h after head injury
markedly attenuated the increased iNOS expression in injured
rats but did not affect the level of expression in intact rats
(Zhao et al., 2002). It is clear that borneol-induced opening
of the BBB is a reversible physiological process rather than a
consequence of pathological damages. Indeed, borneol pro-
tects the structural integrity of the BBB by modulating
vascular endothelial growth factor in rats with cerebral ische-
mia-reperfusion injury (Ni et al., 2011). Borneol combined
with ferulic acid, an agent often used to treat vascular dis-
eases and to prevent thrombosis, suppressed the abnormally
increased BBB permeability caused by cerebral ischemia in
mice (Chen et al., 2010). Borneol also improved cell mem-
brane fluidity in MDCK cells (Chen et al., 2014a) and in
human nasal epithelial cells (Chen et al., 2014b).
Taken together, these findings show that borneol exerts a
biphasic regulatory effect on BBB permeability, i.e. reversibly
opening the BBB under physiological conditions, but protect-
ing the structural integrity of the BBB against pathological
damage.
Possible mechanisms involved in the permeability-
enhancing effects
The permeability-enhancing effects of borneol are closely
associated with the inhibition of efflux protein function, the
enhancement of transmembrane tight junction protein and
predominant enhancement of vasodilatory neurotransmitters
(Figure 2).
ATP-binding cassette (ABC) transporters are a novel family
of ATP-dependent drug efflux proteins of the cell membrane
that pump various foreign substances out of cells. P-glyco-
protein (P-gp), also known as multidrug resistance protein, is
a key member of the ABC transporter family that plays a cru-
cial role in protecting BBB integrity (Ambudkar et al., 1999).
Other ABC transporters are also extensively involved in the
regulation of BBB function (L€oscher & Potschka, 2005). Both
in vitro and in vivo studies have shown that borneol inhibited
the expression of P-gp and other ABC transporters, including
multidrug resistance protein 1 (Mrp1), 1a (Mdr1a) and 1 b
(Mdr1b), resulting in an increase in the amount of Evans blue
and ABC transporter markers rhodamine 123 (Rh123), verap-
amil and digoxin that enter the brain (Fan et al., 2015; Yu
et al., 2011a; Zhang et al., 2011; Yu et al., 2013a,b). These
ABC transporter markers have low brain permeability under
physiological conditions because they are recognized and
inhibited by efflux transporters at the BBB (Perloff et al.,
2003). Similar inhibitory effects of borneol on P-gp were also
observed in MDR1-MDCK cells originated by transfecting
MDCK cells with the MDR1 gene, which encodes for P-gp
(Chen et al., 2013). It appears that the permeability-enhanc-
ing effect of borneol is at least in part derived from its sup-
pression of P-gp and other related efflux protein functions.
Tight junction proteins, particularly transmembrane pro-
teins such as claudins and occludin, play a principal role in
defining epithelial cell polarity, regulating paracellular perme-
ability and conferring barrier function (Paris et al., 2008).
The translocation of claudin-5 and occludin from the cell
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membrane to the cytoplasm was present 30min after the ini-
tiation of borneol treatment and reached peak levels at 1 h,
but returned to the normal pattern 8 h after treatment in
endothelial cells in the blood-optic nerve barrier of rats
(Jin et al., 2011). It is likely that borneol exerts its permeabil-
ity-enhancing effects by reversibly disassembling tight junc-
tion proteins in the BBB.
BBB permeability is directly and indirectly regulated by
multiple neurotransmitters, particularly histamine (Sarker
et al., 1998), serotonin (Cohen et al., 1996), N-methyl-D-aspar-
tate (NMDA) (Meng et al., 1995; Neuhaus et al., 2011) and
acetycholine (Abbruscato et al., 2002). Activation of these
transmitters produces cerebral vasodilation via nitric oxide
and receptors on perivascular astrocytes and microvessel
endothelial cells of the BBB.
Although there is no direct evidence to confirm that the
enhancing effects of borneol on BBB permeability are related
to its modulation of vasodilatory neurotransmitters, systemic
borneol was found to increase the levels of histamine and
serotonin in the hypothalamus (Li et al., 2004, 2006) and lev-
els of L-aspartic acid, glutamate, glycine and c-aminobutyric
acid (GABA) in the corpus striatum of rats (Zhang et al.,
2012). Moreover, the magnitude of the increase in excitatory
amino acid levels was considerably greater than that of the
increase in inhibitory amino acids in the whole brain, result-
ing in a transient elevation in the excitation ratio (excitatory
amino acids versus inhibitory amino acids) (Li et al., 2012).
Natural and synthetic borneol enhanced the actions of GABA
via GABAA receptors in Xenopus laevis oocytes (Granger et al.,
2005) and also modulated nicotinic acetylcholine receptor-
mediated effects in a noncompetitive manner, without affect-
ing the intracellular calcium level in bovine adrenal chromaf-
fin cells (Park et al., 2003).
There is reason to postulate that the transient and revers-
ible effects of borneol in enhancing BBB permeability may be
related to its temporary and predominant enhancement of
vasodilatory neurotransmitters.
Pharmaceutical forms of borneol
To improve the kinetic and toxic profiles of co-administered
drugs and enhance delivery to the brain, various pharma-
ceutical forms of borneol have been developed.
One recent study reported a novel brain glioma-targeting
delivery system called FA-BO-PAMAM/DOX, which was pre-
pared from borneol (BO)-modified PAMAM G5 dendrimer in
conjugation with doxorubicin (DOX) and folic acid (FA) (Xu
et al., 2016). Modification with borneol efficiently boosted
BBB permeability, prolonged half-life time, increased the focal
accumulation and bioavailability of DOX and augmented
anti-tumor efficacy compared to the formulation without bor-
neol. Furthermore, modification with borneol largely reduced
cytotoxicity.
Another brain tumor-targeting delivery system modified
with borneol is the lipid-protein nanocomplex BP-liprosome,
























Figure 2. The permeability-enhancing effects of borneol may be achieved mainly via three mechanisms: the inhibition of efflux protein function; the enhancement
of transmembrane tight junction protein; and predominant enhancement of vasodilatory neurotransmitters. (), inhibitory effects; (þ), enhancing effects; (±)
biphasic regulatory effects.
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by liprosomes (Tang et al., 2015). The nanocomplex is only
approximately 108 nm, and it has high entrapment efficien-
cies of 86% for borneol and 90% for paclitaxel. BP-liprosomes
has a longer release profile and higher accumulation in focal
brain tumor lesions than that without borneol modification.
It exhibits robust anti-tumor efficacy, with 86% versus 62% of
liprosomes conjugated only paclitaxel, and 49% of paclitaxel
solutions (Tang et al., 2015).
Borneol can also be incorporated in ganciclovir-loaded
solid lipid nanoparticles (SLNs) using a modified microemul-
sion method (Ren et al., 2013). Borneol-modified SLNs signifi-
cantly increased the brain distribution of ganciclovir
compared to a ganciclovir injection and SLNs without bor-
neol modification, indicating that borneol-modified SLNs are
an efficient delivery system for transporting drugs to the
brain (Ren et al., 2013).
Huperzine A is a naturally occurring compound that may
have benefits in the treatment of Alzheimer’s disease and
other cognitive impairments. Co-incubation with borneol
increased the uptake of Huperzine A loaded aprotinin-modi-
fied nanoparticles by capillary endothelial cells (Zhang et al.,
2013). Systemic co-administration of borneol further aug-
mented the brain-targeting efficiency and cognition-improv-
ing effects of aprotinin-modified nanoparticles in rats (Zhang
et al., 2013).
High doses of borneol often cause stomach irritation. The
co-loading of borneol and gastrodin, a principal bioactive
ingredient of the Chinese herbal medicine Rhizoma
Gastrodiae (Tian-Ma), into sustained-release solid dispersions
can largely reduce gastric mucosal irritation caused by bor-
neol without sacrificing its targeting efficiency (Cai et al.,
2014). Borneol and gastrodin co-loaded sustained-release
solid dispersions were prepared using ethylcellulose as a sus-
tained-release matrix and hydroxy-propyl methylcellulose as
a retarder. Sustained-release technology appears to be an
effective approach to minimizing stomach irritation while
preserving sufficient transport capacity for brain-targeted
delivery of orally administered borneol (Cai et al., 2014).
Conclusions
Borneol is a naturally occurring compound in a class of
‘orifice-opening’ agents used in TCM for resuscitative pur-
pose. Several lines of evidence confirm that the ‘orifice-open-
ing’ effects of borneol are mainly derived from BBB opening.
The BBB-opening effect of borneol is a reversible physio-
logical process characterized by rapid and transient penetra-
tion through the BBB and highly specific brain regional
distribution. Borneol also protects the structural integrity of
the BBB against pathological damages. The enhancing effects
of borneol on BBB permeability are associated with the
modulation of ABC transporters, including P-gp, tight junc-
tion proteins, and the predominant enhancement of vasodila-
tory neurotransmitters. Systemic co-administration with
borneol improves drug delivery to the brain in a region-,
dose- and time-dependent manner. Various pharmaceutical
forms of borneol, such as FA-BO-PAMAM/DOX, BP-liprosome
and solid lipid nanoparticles, have been developed to
improve the kinetic and toxic profiles of co-administered
drugs and enhance their delivery to the brain.
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